Brief: Shanghai Junshi Biosciences Says JS125 Received Acceptance Notice For Investigational New Drug Application By NMPA
09/07/2024 15:46
July 9 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* JS125 RECEIVED ACCEPTANCE NOTICE FOR INVESTIGATIONAL NEW
DRUG
APPLICATION BY NMPA
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab